These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25630954)

  • 1. Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.
    Magnan H; Goodbody CM; Riedel E; Pratilas CA; Wexler LH; Chou AJ
    Pediatr Blood Cancer; 2015 Apr; 62(4):594-7. PubMed ID: 25630954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult Ewing sarcoma: survival and local control outcomes in 36 patients with metastatic disease.
    Ahmed SK; Robinson SI; Okuno SH; Rose PS; Issa Laack NN
    Am J Clin Oncol; 2014 Oct; 37(5):423-9. PubMed ID: 23388557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
    Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
    Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
    van den Berg H; Paulussen M; Le Teuff G; Judson I; Gelderblom H; Dirksen U; Brennan B; Whelan J; Ladenstein RL; Marec-Berard P; Kruseova J; Hjorth L; Kühne T; Brichard B; Wheatley K; Craft A; Juergens H; Gaspar N; Le Deley MC;
    Eur J Cancer; 2015 Nov; 51(16):2453-64. PubMed ID: 26271204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma.
    Rasper M; Jabar S; Ranft A; Jürgens H; Amler S; Dirksen U
    Pediatr Blood Cancer; 2014 Aug; 61(8):1382-6. PubMed ID: 24729428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.
    Raciborska A; Bilska K; Drabko K; Chaber R; Sobol G; Pogorzała M; Wyrobek E; Połczyńska K; Rogowska E; Rodriguez-Galindo C; Wożniak W
    Pediatr Blood Cancer; 2014 Dec; 61(12):2170-4. PubMed ID: 25163763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes with nondose-dense chemotherapy for Ewing sarcoma: A practical approach for the developing world.
    Parambil BC; Vora T; Sankaran H; Prasad M; Bakshi A; Puri A; Gulia A; Qureshi S; Laskar S; Khanna N; Shah S; Ramadwar M; Kembhavi S; Chinnaswamy G; Banavali S
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28604. PubMed ID: 32706522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
    J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
    Milano GM; Cozza R; Ilari I; De Sio L; Boldrini R; Jenkner A; De Ioris M; Inserra A; Dominici C; Donfrancesco A
    Cancer; 2006 Apr; 106(8):1838-45. PubMed ID: 16532434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
    Paioli A; Luksch R; Fagioli F; Tamburini A; Cesari M; Palmerini E; Abate ME; Marchesi E; Balladelli A; Pratelli L; Ferrari S
    J Chemother; 2014 Feb; 26(1):49-56. PubMed ID: 24091100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ewing Sarcoma: A 15-Year Experience of a Single Center With the MSKCC P6 Treatment Protocol.
    Ben-Ami T; Waldman E; Marc W; Weintraub M; Revel-Vilk S; Fried I
    J Pediatr Hematol Oncol; 2016 Jan; 38(1):38-42. PubMed ID: 26670840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
    J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.
    Wagner MJ; Gopalakrishnan V; Ravi V; Livingston JA; Conley AP; Araujo D; Somaiah N; Zarzour MA; Ratan R; Wang WL; Patel SR; Lazar A; Ludwig JA; Benjamin RS
    Oncologist; 2017 Oct; 22(10):1271-1277. PubMed ID: 28710342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
    Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
    van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
    Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.